What's happening
This bill creates an emergency insulin program in New York to provide affordable access to insulin for uninsured or underinsured individuals.
Why it matters
Creates a formal state infrastructure and funding stream. for emergency insulin access, ensuring that the program will be coordinated, sustained, and able to respond quickly to urgent needs for analog insulin among those at risk.
Mandates participation and action from large pharmacy chains and safety-net healthcare providers. (like 340B clinics), requiring them to register as emergency insulin providers and maintain standing prescriptions—potentially increasing the number and accessibility of locations where people in crisis can get insulin.
Fosters public-private partnerships with insulin manufacturers. , encouraging them to contribute financially to the program and coordinate with the state, which could help drive down costs and expand supply through collaborative efforts.
Limits out-of-pocket costs for recipients. by capping cost-sharing at $100 for a 30-day supply, aiming to prevent cost from being a barrier to life-sustaining medication, while also allowing for a sliding scale based on need.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Create Emergency Insulin Access
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Free Emergency Insulin Access
In Assembly Committee · Health · Sponsor Richard Gottfried
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4883
2021-2022 Regular Sessions
IN SENATE
February 17, 2021
Introduced by Sens. RIVERA, GOUNARDES, KAMINSKY, KRUEGER, MYRIE, PERSAUD, SEPULVEDA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law and the state finance law, in relation to an emergency insulin program
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new article 28-CC to read as follows:
ARTICLE 28-CC
EMERGENCY INSULIN PROGRAM Section 2894. Emergency insulin program.
§ 2894. Emergency insulin program. 1. The commissioner is authorized and directed to establish an emergency insulin program to ensure that recipients of the program can access emergency supplies of analog insulins and related supplies. The commissioner shall immediately engage analog insulin manufacturers to support the state program and facilitate quick access to affordable analog insulins in emergency situations. The commissioner shall establish standards for approval of any emergency insulin program, and analog insulin prescribing, dispensing, distribution, and possession pursuant to this section which may include, but not be limited to, standards for program directors, appropriate clinical oversight, training, record keeping and reporting. The emergency insulin program shall, pursuant to an appropriation or sufficient funds in the emergency insulin program trust fund, be available to recipients no later than April first, two thousand twenty-two.
2. (a) As used in this section:
(i) "Analog insulins" means at a minimum short-acting, rapid-acting, intermediate and long acting insulin drugs approved by the Food and Drug Administration that, when administered, to certain recipients are lifesaving, and help avoid serious adverse effects associated with type one
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00578-01-1
S. 4883 2
diabetes and in some limited cases type two diabetes, and other medications and supplies approved by the department for such purpose.
(ii) "Health care professional" means a person licensed, registered or authorized pursuant to title eight of the education law to prescribe prescription drugs.
(iii) "Pharmacist" means a person licensed or authorized to practice pharmacy pursuant to article one hundred thirty-seven of the education law.
(iv) "Recipient" means a person: (1) diagnosed with type one diabetes, or type two insulin dependent diabetes; and (2) who is at risk of experiencing serious adverse health effects due to a lack of analog insulins; and (3) who is uninsured or underinsured; or (4) an organization registered as an emergency insulin program pursuant to this section.
(b)(i) A health care professional may prescribe by a patient-specific or non-patient-specific prescription, dispense or distribute, directly or indirectly, analog insulins to a recipient.
(ii) A pharmacist may dispense analog insulins, through a patient-specific or non-patient-specific prescription pursuant to this paragraph, to a recipient.
(iii) The provisions of this paragraph shall not be deemed to require a prescription for any analog insulins that do not otherwise require a prescription; nor shall it be deemed to limit the authority of a health care professional to prescribe, dispense or distribute, or of a pharmacist to dispense, analog insulins under any other provision of law.
(iv) Any pharmacy with twenty or more locations in the state, and any facility established pursuant to article twenty-eight of this chapter which has a drug discount program authorized by section 340B of the Federal Public Health Service act 42 U.S.C § 256b shall pursue or maintain a non-patient-specific prescription with an authorized health care professional to dispense analog insulins to a recipient upon request, as authorized by this section; and register with the department as an emergency insulin program no later than January first, two thousand twentytwo.
3. Use or dispensing of analog insulins pursuant to this section shall be considered first aid or emergency treatment for the purpose of any statute relating to liability.
4. The commissioner shall immediately begin to work with analog insulin manufacturers in creating such program to ensure they are working with the state in a public-private partnership to support the state's streamlined emergency insulin program that may replicate patient support programs such manufacturers have. A manufacturer may contribute to the program through the emergency insulin program trust fund established pursuant to section ninety-five-j of the state finance law.
5. The commissioner may establish a sliding scale for cost sharing for certain recipients which shall not exceed one hundred dollars for a thirty-day supply of analog insulins and related supplies.
6. The commissioner shall publish findings on the emergency insulin program including but not limited to the number of programs established, the number of recipients served, the types and amounts of analog insulins provided, the costs and savings associated with the program, and what public-private partnerships the state has facilitated to support this program to the governor and the chairs of the senate and assembly health committees within one year of the effective date of this article and every two years thereafter.
§ 2. The state finance law is amended by adding a new section 95-j to read as follows:
S. 4883 3
§ 95-j. Emergency insulin program trust fund. 1. There is hereby established in the joint custody of the state comptroller and the commissioner of taxation and finance a special fund to be known as the "emergency insulin program trust fund".
2. Such fund shall consist of all monies appropriated for its purpose and all monies received, or to be paid into or credited to such fund by analog insulin manufacturers pursuant to subdivision four of section twenty-eight hundred ninety-four of the public health law. Nothing contained herein shall prevent the state from receiving assessments, grants, gifts or bequests for the purposes of the fund as defined in this section and depositing them into the fund according to law.
3. Monies of the fund shall be expended only to support the emergency insulin program established pursuant to article twenty-eight-CC of the public health law administered by the commissioner of health and for funding emergency access to analog insulins.
4. Monies shall be payable from the fund on the audit and warrant of the comptroller on vouchers approved and certified by the commissioner of health.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law and the state finance law, in relation to an emergency insulin program
Purpose or general idea of bill
To create an Emergency Insulin Program to ensure that those dependent on insulin for their survival can access emergency supplies.
Summary of specific provisions
Section 1 of the bill establishes a new article 28-CC of the public health law creating an Emergency Insulin Program. The program shall ensure that recipients of the program can access emergency supplies of analog insulins and related supplies no later than April 1, 2021, assum- ing an appropriation or sufficient funds are in the program trust fund established pursuant to section two. A recipient is a person diagnosed with type one diabetes, or type two insulin dependent diabetes and who is at risk of experiencing serious adverse health effects due to a lack of analog insulins, and who is uninsured or underinsured. It also allows providers to prescribe analog insulins under a non-patient specific prescription and a pharmacist may dispense through a non-patient specif- ic prescription to a recipient, similar to the successful state opioid prevention program which ensures access to naloxone to reverse over- doses.
Read the full memo (1,169 words)
This section also requires any pharmacy with twenty or more locations in the state and any article 28 facility with a 340B drug discount program to pursue or maintain a non-patient specific prescription to dispense analog insulins and to register with the department as an emergency insulin program by January 1, 2021.
This section further directs the Commissioner of Health to immediately begin to work with analog insulin manufacturers in creating such programs to have a public-private partnership to support the state's streamlined Emergency Insulin Program that may replicate patient support programs such manufactures have. It also allows the Commissioner to establish a sliding scale for cost sharing for certain recipients which shall not exceed one hundred dollars for a thirty day supply of analog insulins and related supplies. Finally, this section directs the Commis- sioner to publish findings on the program and share them with the Gover- nor and legislature within one year of the effective date and every two years thereafter.
Section 2 amends the state finance law by adding a new section 97-tttt which creates a special revenue fund in the joint custody of the state comptroller and the commissioner of taxation and finance to be known as the Emergency Insulin Program Trust Fund to support the Emergency Insu- lin Program.
Section 3 provides for the effective date.
Justification
2.1 million New Yorkers have diabetes and 30% of type two diabetics are insulin dependent. There are 20,000 hospitalizations in New York State each year with a principal diagnosis of diabetes related complications including diabetic ketoacidosis. Type 1 and some Type 2 diabetics depend upon insulin for their very survival. In 2016, the average person with type 1 diabetes incurred annual insulin costs of $5,705.00. While some pay less, many others pay many times this amount. When patients can't afford insulin, which can cost thousands of dollars even for those who are insured, patients can resort to rationing the little medication they can afford. In fact, one study found that one in four people with type 1 diabetes admitted to not taking their insulin as prescribed, or rationing, due to the cost. Complications from rationing insulin are extreme and can lead to amputations, Diabetic KETOACIDOSIS, also referred to as DKA, and even death.
This legislation creates an Emergency Insulin Program, modeled after New York State's Opioid Prevention Program which has made access to life saving Naloxone to reverse an opioid overdose widely available in our state. Under the Emergency Insulin Program, individuals who are unin- sured or underinsured would be able to get analog insulin through a non-patient specific prescription at certain pharmacies, including clin- ic and hospital pharmacies. The Department of Health would be able to establish a sliding scale for certain cost sharing, which would be capped at $100 for a thirty day supply of insulins and supplies.
The bill directs the Department of Health to immediately engage analog insulin manufactures to support the state program and facilitate quick access to affordable analog insulin in emergency situations through a public private partnership to streamline existing patient support programs such manufactures have. The three manufactures of analog insu- lin each have programs designed to help people access their products at a reduced rate or for free, however each program is different and advo- cates argue they are difficult to access, especially in emergency situ- ations. Recognizing that manufactures want to make sure everyone can access the life-saving medications they hold patents on, this bill establishes an Emergency Insulin Program Trust fund to accept funds for the statewide program. Like New York's highly successful Opioid Prevention Program which makes naloxone widely available, this program would allow for non-patient specific prescriptions for analog insulins and utilize chain pharmacies and 340B pharmacies, which are able to provide the lowest cost medications, to distribute the insulins and supplies to recipients who qualify.
While it is true there are some types of human insulin that can be accessed over the counter and for a relatively low fee, these are often referred to as "dead in bed" insulin because they do not provide the level of support many type 1 and some type 2 diabetics require.
These low cost human insulins are less commonly prescribed by doctors precisely because of their unpredictable rate of absorption, which can result in more frequent low and high blood sugars. They require more monitoring and more supplies and, according to advocates when people transition from the newer, more costly analog insulins the risk of dead in bed syndrome is greatly increased. In recent years, the Opioid Over- does Prevention Program has been expanded to provide access in pharma- cies, not just through community based organizations. Like overdose, the risk of death from a lack of insulin occurs far too often and quickly. New York State must do all it can to make sure that diabetics who depend on insulin for their survival can access emergency supplies of analog insulin, just as we currently insure the friends, families and first responders are equipped with like saving naloxone in the case of an overdose. There is no question that a person who depends on daily insu- lin for their survival is at grave risk without timely access to afford- able insulin. Nobody should die from rationing or running out of insu- lin, or from being forced to switch to less reliable human insulin. The Emergency Insulin Program can make sure New York, with the cooperation of manufac- tures of analog insulins, is doing all it can to ensure those in need can access this life saving medication.
Prior legislative history
2019-2020: S7771/A10054 Gottfried
Fiscal implications
To be determined, but potential savings as expensive hospitalizations as a result of severe adverse reactions from patients rationing or running out of insulin is avoided.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.